What question did this study set out to answer?

To evaluate the impact of prophylactic anakinra on neurotoxicity and infection in patients undergoing CD19 CAR T-cell therapy.

December 8, 2025Blood

Real-world assessment of prophylactic anakinra on neurotoxicity after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis

View Full Paper

Ask AI

Bookmark

Authors

NENeela EaswarCornell University AAAnna AlperovichCornell University MMMateo Mejia-SaldarriagaCornell University

Discussion

Member takes

Implication

Retrospective analysis shows anakinra associates with higher infection rates but no reduction in neurotoxicity in lymphoma patients receiving CAR T therapy, suggesting caution in use.

Key Points

To evaluate the impact of prophylactic anakinra on neurotoxicity and infection in patients undergoing CD19 CAR T-cell therapy.
Retrospective cohort study of R/R B-cell lymphoma patients
Comparison of anakinra prophylaxis group vs historical control
Analysis included inverse probability of treatment weighting for covariate balance
Outcomes assessed included grade ≥3 ICANS, CRS, infection rates, and survival metrics
Logistic regression used to calculate odds ratios for toxicity and survival outcomes.
No significant difference in grade ≥3 ICANS between anakinra (13.0%) and control (9.8%) groups (p = 0.57)
Anakinra patients had increased rates of any grade ICANS (39.6% vs 23.4%, p = 0.046)
Higher grade 3+ infection rates in anakinra group (22.5% vs 8.0%, p = 0.006)
No difference in median EFS or OS between groups (p = 0.32 and p = 0.72)
Analysis suggests no survival benefit from anakinra but raises concerns about its routine use.

Cite This Study

Easwar et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4c5 https://doi.org/10.1182/blood-2025-712

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows anakinra associates with higher infection rates but no reduction in neurotoxicity in lymphoma patients receiving CAR T therapy, suggesting caution in use.

Real-world assessment of prophylactic anakinra on neurotoxicity after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world assessment of prophylactic anakinra on neurotoxicity after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider